Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy

W. Barcellini, P. L. Meroni, D. Frasca, C. Sguotti, M. O. Borghi, C. Uberti-Foppa, P. Buzzetti, A. Lazzarin, G. Doria, M. Moroni

Research output: Contribution to journalArticle

Abstract

The effect of thymopentin treatment on the immune defects in drug addicts with persistent generalized lymphadenopathy and HTLV-III infection was investigated. Thymopentin was administered subcutaneously at two different dose schedules: 50 mg three times a week for 3 weeks (first cycle) and 50 mg/week for 3 months (second cycle). After the first cycle an increased number of OKT4+ lymphocytes and an improvement of PWM-induced blastogenesis and IgG synthesis in vitro was observed. The second cycle was unable to modify the same immune parameters in vitro. The treatment had no effect on the PHA responsiveness and on PHA-induced interleukin 2 production. The significance and the prognostic value of these findings are discussed in terms of the clinical evolution of the syndrome.

Original languageEnglish
Pages (from-to)537-543
Number of pages7
JournalClinical and Experimental Immunology
Volume67
Issue number3
Publication statusPublished - 1987

Fingerprint

Thymopentin
Drug Users
Lymphocyte Count
Lymphocyte Activation
HIV Infections
Interleukin-2
Appointments and Schedules
Immunoglobulin G
Therapeutics
In Vitro Techniques
Lymphadenopathy

ASJC Scopus subject areas

  • Immunology

Cite this

Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy. / Barcellini, W.; Meroni, P. L.; Frasca, D.; Sguotti, C.; Borghi, M. O.; Uberti-Foppa, C.; Buzzetti, P.; Lazzarin, A.; Doria, G.; Moroni, M.

In: Clinical and Experimental Immunology, Vol. 67, No. 3, 1987, p. 537-543.

Research output: Contribution to journalArticle

@article{a109635812fa423e81f6696e38ac7b8a,
title = "Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy",
abstract = "The effect of thymopentin treatment on the immune defects in drug addicts with persistent generalized lymphadenopathy and HTLV-III infection was investigated. Thymopentin was administered subcutaneously at two different dose schedules: 50 mg three times a week for 3 weeks (first cycle) and 50 mg/week for 3 months (second cycle). After the first cycle an increased number of OKT4+ lymphocytes and an improvement of PWM-induced blastogenesis and IgG synthesis in vitro was observed. The second cycle was unable to modify the same immune parameters in vitro. The treatment had no effect on the PHA responsiveness and on PHA-induced interleukin 2 production. The significance and the prognostic value of these findings are discussed in terms of the clinical evolution of the syndrome.",
author = "W. Barcellini and Meroni, {P. L.} and D. Frasca and C. Sguotti and Borghi, {M. O.} and C. Uberti-Foppa and P. Buzzetti and A. Lazzarin and G. Doria and M. Moroni",
year = "1987",
language = "English",
volume = "67",
pages = "537--543",
journal = "Clinical and Experimental Immunology",
issn = "0009-9104",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Effect of subcutaneous thymopentin treatment in drug addicts with persistent generalized lymphadenopathy

AU - Barcellini, W.

AU - Meroni, P. L.

AU - Frasca, D.

AU - Sguotti, C.

AU - Borghi, M. O.

AU - Uberti-Foppa, C.

AU - Buzzetti, P.

AU - Lazzarin, A.

AU - Doria, G.

AU - Moroni, M.

PY - 1987

Y1 - 1987

N2 - The effect of thymopentin treatment on the immune defects in drug addicts with persistent generalized lymphadenopathy and HTLV-III infection was investigated. Thymopentin was administered subcutaneously at two different dose schedules: 50 mg three times a week for 3 weeks (first cycle) and 50 mg/week for 3 months (second cycle). After the first cycle an increased number of OKT4+ lymphocytes and an improvement of PWM-induced blastogenesis and IgG synthesis in vitro was observed. The second cycle was unable to modify the same immune parameters in vitro. The treatment had no effect on the PHA responsiveness and on PHA-induced interleukin 2 production. The significance and the prognostic value of these findings are discussed in terms of the clinical evolution of the syndrome.

AB - The effect of thymopentin treatment on the immune defects in drug addicts with persistent generalized lymphadenopathy and HTLV-III infection was investigated. Thymopentin was administered subcutaneously at two different dose schedules: 50 mg three times a week for 3 weeks (first cycle) and 50 mg/week for 3 months (second cycle). After the first cycle an increased number of OKT4+ lymphocytes and an improvement of PWM-induced blastogenesis and IgG synthesis in vitro was observed. The second cycle was unable to modify the same immune parameters in vitro. The treatment had no effect on the PHA responsiveness and on PHA-induced interleukin 2 production. The significance and the prognostic value of these findings are discussed in terms of the clinical evolution of the syndrome.

UR - http://www.scopus.com/inward/record.url?scp=0023152332&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023152332&partnerID=8YFLogxK

M3 - Article

C2 - 3301099

AN - SCOPUS:0023152332

VL - 67

SP - 537

EP - 543

JO - Clinical and Experimental Immunology

JF - Clinical and Experimental Immunology

SN - 0009-9104

IS - 3

ER -